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Sudden unexpected death is an important category of mortality in the population with epilepsy. Possible risk factors have been
identified from an epidemiological study of this phenomenon, but the exact mechanisms remain unclear. Some of these factors
include: male sex; age 20–40 years; generalized seizures; poor seizure control; poor compliance with medication.
Case-control studies now being undertaken are the next step in the elucidation of these factors. The results of one study to
date reinforce the view that, in the majority of cases, sudden unexpected death in epilepsy (SUDEP) is a seizure-related event.
This suggests that improvement in seizure control and the avoidance of polytherapy may be important in risk reduction.
An ongoing exploratory case-control study in the UK has identified 154 cases of SUDEP, each of which will have four
controls, matched for age and geographical location, in order to examine the influence of various parameters on the risk of
sudden death.
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INTRODUCTION
Individuals with epilepsy have a mortality rate 2–
3 times that of the general population1–3, attributable
to both the underlying disease and epilepsy it-
self. Epilepsy-related deaths are either seizure or
treatment related. The most common category of
seizure-related death is sudden unexpected death in
epilepsy (SUDEP). The exact mechanisms underly-
ing SUDEP are unclear so risk factors have, to date,
been identified from descriptive epidemiological stud-
ies. These factors are described here.
Age and sex
The fact that the age group 20–40 years seems most
susceptible is borne out by various studies. In a
study of SUDEP in an outpatient cohort conducted by
Nashef et al.4 the mean age of death was 28.6 years.
The average age of death in the outpatient group ex-
amined by Timmings was 35 years5 with similar re-
sult being found by Leestma et al.6, 7 in their work.
The majority of studies have reported more deaths in
males5, 7, 8, although this is not always the case4, 9.
Epilepsy syndrome
The Rochester study reported more sudden deaths
among those with localization-related symptomatic
epilepsy10; in most, but not all studies, the majority of
SUDEP victims have had localization-related epilepsy.
In post-mortem series a pathological substrate for the
epilepsy is found in 34–70% of cases6, 7, 11. In the in-
terview study conducted by Nashef12, 9 of 26 individ-
uals who died had a history of idiopathic localization-
related epilepsy, and in the study by Timmings13,
which examined mortality in a cohort attending an
epilepsy clinic, the majority of deaths occurred in in-
dividuals with idiopathic generalized epilepsy. Derby
et al.14 found that those with cryptogenic epilepsy
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were more at risk of SUDEP than those with symp-
tomatic localization-related epilepsy. The recent case-
control study by Nilsson et al.15 found an increased
risk of SUDEP among men with idiopathic gen-
eralized epilepsy compared with localization-related
symptomatic epilepsy.
Seizure type and frequency
The majority of victims of SUDEP have a history
of generalized tonic–clonic seizures (GTCS)4, 5, 7, 9, 16.
Such deaths have, however, been reported in associ-
ation with other seizure types17. Incidence data sug-
gest that the risk of sudden-death is related to seizure
control, higher sudden death rates being found in co-
horts with intractable epilepsy4, 16–18. On the other
hand, population-based studies such as the Medical
Research Council (MRC) study of drug withdrawal
and the NGPSE, where a large number of patients had
well-controlled epilepsy or were in remission, identi-
fied few sudden deaths2, 19.
Antiepileptic drugs (AEDs) and compliance
At present there is no evidence that any particular anti-
convulsant can influence the risk of SUDEP although
there are anecdotal reports of bradyarrhythmia and si-
nus arrest being associated with carbamazepine20–22.
Some authors suggest that the proportion of SUDEP
victims taking carbamazepine is significantly higher
than the proportion taking this AED in the rest of the
population with epilepsy23. There are reports in the
literature of two cases where patients in both cases
were taking oxcarbazepine and vigabatrin, and in one
case additional lamotrigine, developed SIADH (syn-
drome of inappropriate antiduretic hormone secretion)
and died suddenly. The authors recommend electrolyte
analysis in victims of SUDEP particularly when on
carbamazepine and oxcarbazepine24.
Tennis et al.25 found that those on polytherapy were
over represented among cases compared with controls,
with a 1.7-fold increase in risk for each AED added.
The conventional wisdom thus far has been that AED
number is a surrogate marker for epilepsy severity.
Changes in AED therapy may also increase the risk
of SUDEP for an individual with epilepsy, perhaps by
influencing reflex function. Lip and Brodie8 found that
5 of 12 cases had had a recent change in AED therapy,
mostly involving a dose reduction or drug withdrawal.
Poor compliance with medication appears to be as-
sociated with an increased risk of SUDEP as in the
study by Lip and Brodie8 where poor compliance was
reported in 25% of cases.
Many cases of SUDEP are associated with subther-
apeutic anticonvulsant levels at post-mortem26. Some
have taken this to indicate non-compliance with med-
ication which is a feature of a number of cases of
SUDEP7, 27; however, the relationship of these lev-
els to ante-mortem levels is uncertain28. Investigators
have found that ante-mortem serum levels of carba-
mazepine were not significantly different from whole-
blood concentrations taken up to 72 hours after death.
Ante-mortem phenytoin levels in whole blood were
only 65% of the serum concentration and were only
35% of serum concentrations when measured at post-
mortem29.
Witnessed seizures
Terrence et al.30 found 9 of 37 patients’ died as a re-
sult of a single seizure or a few seizures in the pres-
ence of witnesses. Lip and Brodie8 found that 3 of
the 12 deaths they identified were witnessed, with
only one having a convulsive seizure prior to death.
Leestma7 reported that in 38%, or 23 out of 60 cases,
collapse was witnessed and a seizure was seen in 14 of
these. Hirsch and Martin31 report 42% of cases being
witnessed and, in a study of SUDEP in the Republic of
Ireland32, 1 of 15 cases of death was witnessed as hav-
ing been preceded by a generalized seizure. Nashef12.
in the interview study, found that 2 of 26 deaths were
witnessed.
Most authors report a substantial proportion of pa-
tients being found dead in bed32. It has been suggested
that obstructive apnoea may be a possible mechanism
although the circumstances surrounding many cases
would not support this view. It is important to note
that, in a study of SUDEP in a residential school for
children with epilepsy who were closely supervised at
night, there was a lower incidence during term time
and no cases were witnessed. Therefore, it may be that
attention to the recovery of the individual following
a seizure, and positioning or stimulation if necessary,
may be important in the prevention of SUDEP16.
Other factors
Other factors which may alter the risk of SUDEP in
those with epilepsy include neurological deficit and
learning difficulty, which may be markers for epilepsy
severity18. The same may be true of the fact that there
has been an observed increased use of psychotropic
drugs in the SUDEP population compared with that in
the population with epilepsy as a whole25. It should
be noted that there is also an increased incidence
of sudden unexpected death in the psychiatric pop-
ulation. Such deaths were noted prior to the advent
of phenothiazine therapy but since their introduction
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these drugs have been repeatedly associated with such
deaths, although the nature of any relationship remains
unclear33, 34. The Afro-American population may be
more at risk of sudden death, although this observa-
tion may be a reflection of the increased prevalence of
epilepsy in this population7. An excessive alcohol in-
take has also been found in some cases of SUDEP7, 31.
Case-control studies
Case-control studies are the next step in identifying
factors which influence the risk of sudden death for an
individual with epilepsy.
Initial attempts at case-control study involved highly
selected case series and a paucity of suitable con-
trols. The results of the case-control study undertaken
by Nilsson et al.15 in Sweden have recently been
published. The study population comprised those be-
tween 15 and 70 years living in Stockholm who had at
least one admission for the assessment of epilepsy be-
tween 1980 and 1989. Cases studied were those who
had died, epilepsy having been written on the death
certificate and whose medical record and autopsy re-
port were compatible with SUDEP, and were only in-
cluded if they had been taking one of the AEDs car-
bamazepine, phenytoin or sodium valproate continu-
ously for the previous year. The study, therefore, does
not address recent or untreated cases.
Fifty-seven cases, 34 men and 23 women were iden-
tified of whom 91% had undergone post-mortem ex-
amination. The relative risk of SUDEP increased with
increasing number of seizures per year. The estimated
recovery rate (RR) was 10.16 (2.94–35.18) in those
with more than 50 seizures per year compared with
those who had two seizures per year and RR was 23.2
(3.16–170.28) when those having any seizure were
compared with those who were seizure free.
The risk of SUDEP increased with increasing num-
bers of concomitant AEDs. There was a risk factor
of 9.89 for three AEDs compared with monotherapy
and was independent of seizure control. Other ma-
jor risk factors were frequent changes of AED dosage
compared with unchanged dosage, RR 6.08 (1.99–
18.56). There was an 18-fold increase in RR associ-
ated with epilepsy in childhood compared with on-
set at over 45 years of age. The association between
SUDEP risk and early onset of epilepsy and SUDEP
risk and seizure frequency was weaker for women than
men, whereas the association between dosage change
and increased risk was stronger in female patients.
Dementia has been reported as a possible risk factor
for SUDEP, RR 6 (1.5–23.99). It may have been pre-
viously unreported because of the younger age group
included in previous studies. This work did not con-
firm any association between alcohol intake and risk
of SUDEP in this patient group.
This case-control study reinforces the theory that
SUDEP is a seizure-related event and that improve-
ment of seizure control and the avoidance of polyther-
apy may be important in the prevention of SUDEP,
but intractable seizures and polytherapy with trials of
new treatment go together in clinical practice. While
polytherapy may be at times unavoidable, abrupt drug
changes certainly are and should be avoided. Further
information on the drug changes in the study, and of
the rate of SUDEP in subjects after AED withdrawal,
would be of great interest as the physician recom-
mending medication needs to balance the risk of in-
stability consequent to medication against the prospect
of improved control. Gradual changes are strongly rec-
ommended.
The population-based study of SUDEP incidence
conducted by Ficker et al.9 has already been alluded
to. Of the nine cases identified most had a history of
GTCS and absent or subtherapeutic AED levels were
a characteristic of these cases. Although the authors
planned to undertake statistical analysis with a view
to risk-factor identification, it proved impossible given
the small number of cases identified.
An ongoing case-control study
In an ongoing exploratory case-control study we seek
to examine the influence of various parameters on the
risk of sudden death. There are 154 cases, between the
ages of 16 and 50 years, which have been identified
by:
• coroners in England and Wales, in fact we are
uniquely placed in the UK as 90% of SUDEP cases
are referred to the coroner;
• neurologists via the British Neurological Surveil-
lance Unit;
• the charity ‘Epilepsy Bereaved?’ with whose as-
sistance approximately 50 bereaved families have
been interviewed.
Cases all have a history of active epilepsy and ful-
fil the following definition. They are sudden, unex-
pected, witnessed or unwitnessed, non-traumatic and
non-drowning death in an individual with epilepsy,
with or without evidence for a seizure and excluding
documented status epilepticus where post-mortem ex-
amination does not reveal a cause for death. Back-
ground information has been obtained from general
practitioners, hospital consultants and, where appro-
priate, coroners. Where necessary GPs were traced
through the Office for National Statistics.
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Fig. 3: Evidence for recent seizure.
Each case will have four controls matched for age
and geographical location. The help of the MRC Epi-
demiology and Preventive Medicine Unit has been en-
listed in this endeavour and practices in the appropriate
areas identified from the MRC General Practice Re-
search Framework. Randomly selected suitable con-
trols are identified and relevant information extracted
from the case notes. The factors under examination
include epilepsy syndrome, seizure type and control,
treatment history and compliance, other factors such
as alcohol intake, ECG changes and supervision at
night will also be included. Logistic regression anal-
ysis will be performed and a risk factor score deter-
mined. We aim to offer advice to those with epilepsy,
their families and physicians on strategies to reduce
the risk of SUDEP.
The 154 cases identified comprise 97 men and
57 women with a mean age of 32 years. The sources of
referral are illustrated in Fig. 1. The majority of indi-
viduals were found dead in bed and there was evidence
to support a recent seizure in the majority (Figs 2
and 3)
Twenty-one cases were witnessed, the majority oc-
curring in association with a GTCS and, as we previ-
ously reported, witnesses often stated that victims ap-
peared to have breathing difficulties prior to death35.
Thus far our work lends supporting evidence to the
belief that SUDEP is a seizure-related event. The opti-
mization of seizure control may play an important role
in the prevention of these tragic deaths and the risk
of SUDEP may need to be considered whenever deci-
sions are made about alterations in therapy. Our work
also suggests that a witnessed seizure is less likely to
be fatal, and it may be that attention to recovery fol-
lowing a seizure and positioning or stimulation, if nec-
essary, may be important in the prevention of SUDEP.
We look forward with interest to the identification of
risk factors.
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